Insulin and diabetes drug manufacturers want a federal district judge to dismiss 340B-related antitrust changes against them.

Insulin and Diabetes Drug Makers Ask Judge to Dismiss 340B-Related Antitrust Charges

U.S. manufacturers of insulin and diabetes-related treatments asked a federal judge on Friday to dismiss two health centers’ antitrust class action over the companies’ denials of 340B pricing when covered entities use contract pharmacies.

In a Nov. 11 joint motion filed in federal district court in Rochester, N.Y., the companies (Sanofi, Lilly, Novo Nordisk, and AstraZeneca) say that the health centers (Mosaic Health of upstate New York and Central Virginia Health Services) lack standing to sue and offer no direct or circumstantial evidence of conspiracy to restrain trade.

U.S. manufacturers of insulin and diabetes-related treatments asked a federal judge on Friday to dismiss two health centers’ antitrust class action over the companies’ denials of 340B pricing when covered entities use contract pharmacies.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report